LGND vs. CORT
LGND (Ligand Pharmaceuticals Incorporated) and CORT (Corcept Therapeutics Incorporated) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, LGND returned 7.10%/yr vs 28.72%/yr for CORT. At a 0.25 correlation, their price movements are largely independent.
Performance
LGND vs. CORT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LGND achieves a 23.98% return, which is significantly lower than CORT's 108.76% return. Over the past 10 years, LGND has underperformed CORT with an annualized return of 7.10%, while CORT has yielded a comparatively higher 28.72% annualized return.
LGND
- 1D
- 0.70%
- 1M
- 2.64%
- YTD
- 23.98%
- 6M
- 21.43%
- 1Y
- 129.02%
- 3Y*
- 46.01%
- 5Y*
- 15.23%
- 10Y*
- 7.10%
CORT
- 1D
- 2.04%
- 1M
- 40.79%
- YTD
- 108.76%
- 6M
- -13.17%
- 1Y
- 4.52%
- 3Y*
- 46.18%
- 5Y*
- 27.68%
- 10Y*
- 28.72%
LGND vs. CORT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
LGND Ligand Pharmaceuticals Incorporated | 23.98% | 76.45% | 50.03% | 6.92% | -56.75% | 55.31% | -4.64% | -23.15% | -0.90% | 34.76% |
CORT Corcept Therapeutics Incorporated | 108.76% | -30.94% | 55.14% | 59.92% | 2.58% | -24.31% | 116.20% | -9.43% | -26.02% | 148.76% |
Correlation
The correlation between LGND and CORT is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.31 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.29 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.33 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.33 |
Correlation (All Time) Calculated using the full available price history since Apr 15, 2004 | 0.25 |
Fundamentals
LGND:
$4.66B
CORT:
$7.59B
LGND:
$7.57
CORT:
$0.41
LGND:
30.96
CORT:
177.15
LGND:
0.27
CORT:
88.25
LGND:
17.32
CORT:
10.96
LGND:
4.67
CORT:
11.89
LGND:
$274.48M
CORT:
$769.10M
LGND:
$221.02M
CORT:
$755.64M
LGND:
$253.90M
CORT:
$3.66M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LGND vs. CORT — Risk / Return Rank
LGND
CORT
LGND vs. CORT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ligand Pharmaceuticals Incorporated (LGND) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LGND | CORT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.47 | ||
| Sortino ratioReturn per unit of downside risk | +3.27 | ||
| Omega ratioGain probability vs. loss probability | 1.52 | 1.14 | +0.38 |
| Calmar ratioReturn relative to maximum drawdown | 9.23 | 0.07 | +9.16 |
| Martin ratioReturn relative to average drawdown | 23.23 | 0.13 | +23.10 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| LGND | CORT | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 3.53 | 0.06 | +3.47 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.35 | 0.37 | -0.03 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.16 | 0.43 | -0.27 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.11 | 0.11 | 0.00 |
Drawdowns
LGND vs. CORT - Drawdown Comparison
The maximum LGND drawdown since its inception was -93.34%, roughly equal to the maximum CORT drawdown of -94.28%. Use the drawdown chart below to compare losses from any high point for LGND and CORT.
Loading charts...
Drawdown Indicators
| LGND | CORT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.34% | -94.28% | +0.94% |
Max Drawdown (1Y)Largest decline over 1 year | -14.07% | -64.40% | +50.33% |
Max Drawdown (3Y)Largest decline over 3 years | -37.25% | -71.85% | +34.60% |
Max Drawdown (5Y)Largest decline over 5 years | -70.11% | -71.85% | +1.74% |
Max Drawdown (10Y)Largest decline over 10 years | -81.94% | -71.85% | -10.09% |
Current DrawdownCurrent decline from peak | -14.61% | -36.39% | +21.78% |
Average DrawdownAverage peak-to-trough decline | -44.57% | -53.45% | +8.88% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.57% | 35.28% | -29.71% |
Volatility
LGND vs. CORT - Volatility Comparison
The current volatility for Ligand Pharmaceuticals Incorporated (LGND) is 14.22%, while Corcept Therapeutics Incorporated (CORT) has a volatility of 16.23%. This indicates that LGND experiences smaller price fluctuations and is considered to be less risky than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LGND | CORT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.22% | 16.23% | -2.01% |
Volatility (6M)Calculated over the trailing 6-month period | 27.82% | 85.05% | -57.23% |
Volatility (1Y)Calculated over the trailing 1-year period | 36.72% | 76.53% | -39.81% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 44.07% | 74.50% | -30.43% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 45.38% | 67.20% | -21.82% |
Dividends
LGND vs. CORT - Dividend Comparison
Neither LGND nor CORT has paid dividends to shareholders.
Financials
LGND vs. CORT - Financials Comparison
This section allows you to compare key financial metrics between Ligand Pharmaceuticals Incorporated and Corcept Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LGND vs. CORT - Profitability Comparison
LGND - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Ligand Pharmaceuticals Incorporated reported a gross profit of 0.00 and revenue of 51.72M. Therefore, the gross margin over that period was 0.0%.
CORT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a gross profit of 162.02M and revenue of 164.90M. Therefore, the gross margin over that period was 98.3%.
LGND - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Ligand Pharmaceuticals Incorporated reported an operating income of 17.37M and revenue of 51.72M, resulting in an operating margin of 33.6%.
CORT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported an operating income of -49.60M and revenue of 164.90M, resulting in an operating margin of -30.1%.
LGND - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Ligand Pharmaceuticals Incorporated reported a net income of -13.35M and revenue of 51.72M, resulting in a net margin of -25.8%.
CORT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a net income of -31.20M and revenue of 164.90M, resulting in a net margin of -18.9%.
Frequently Asked Questions
LGND and CORT have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CORT has higher volatility (16.23%) compared to LGND (14.22%). In terms of maximum drawdown, LGND dropped -93.34% vs CORT's -94.28%.
LGND currently has the higher Sharpe Ratio (3.53 vs 0.06), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LGND and CORT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer